Frederic Fiteni

Montpellier, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib.

Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib.

Journal: Breast cancer research and treatment

Published: March 31, 2026

Determinants of return to work in long-term metastatic breast cancer survivors: Results of a multicenter French cohort.

Determinants of return to work in long-term metastatic breast cancer survivors: Results of a multicenter French cohort.

Journal: Bulletin du cancer

Published: February 20, 2026

Overview of current practices and management of genitourinary syndrome in breast cancer patients

Overview of current practices and management of genitourinary syndrome in breast cancer patients

Journal: Bulletin du cancer

Published: December 21, 2025

Quality-of-life trajectories in advanced urothelial carcinoma patients under pembrolizumab: Results from the French AMI observational cohort trial.

Quality-of-life trajectories in advanced urothelial carcinoma patients under pembrolizumab: Results from the French AMI observational cohort trial.

Journal: Bulletin du cancer

Published: November 19, 2025

Title Not Found

Title Not Found

Journal: Sante publique (Vandoeuvre-les-Nancy, France)

Published: October 06, 2025

Patient-Reported Outcomes in Early-Phase Oncology Clinical Trials: A Stepping Stone to a Patient-Centered Drug Development.

Patient-Reported Outcomes in Early-Phase Oncology Clinical Trials: A Stepping Stone to a Patient-Centered Drug Development.

Journal: The patient

Published: July 12, 2025

Implementation of telemonitoring in oncology : AFSOS Guidelines for Routine Medical Care in 2025

Implementation of telemonitoring in oncology : AFSOS Guidelines for Routine Medical Care in 2025

Journal: Bulletin du cancer

Published: July 02, 2025

Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study.

Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study.

Journal: Breast cancer research and treatment

Published: July 01, 2025

SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.

SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.

Journal: Therapeutic advances in medical oncology

Published: June 06, 2025

Management of cancer treatment-related fatigue in advanced breast cancer patients: an expert committee's opinion.

Management of cancer treatment-related fatigue in advanced breast cancer patients: an expert committee's opinion.

Journal: Frontiers in oncology

Published: April 24, 2025

Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients.

Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients.

Journal: Cancer medicine

Published: October 20, 2024

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Journal: British journal of cancer

Published: March 31, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026